-
Novartis AG (NYSE:NVS) Q1 2025 Earnings Call Transcript
30 Apr 2025 12:27 GMT
… Transcript April 29, 2025
Novartis AG beats earnings expectations. … very robust direct to consumer advertising campaign. Now in terms of … use your email to send marketing emails about our services. … as continued very good, brand performance, and I think …
-
As Novartis builds momentum with new drug launches, CEO says he's 'comfortable' navigating US tariffs
29 Apr 2025 21:10 GMT
… grown its new-to-brand share to 60%, Novartis CEO Vas Narasimhan … -consumer advertising campaign.”
Thanks to strong growth from eight priority brands, Novartis beat … .
Projecting confidence amid tariff uncertainty
Novartis is “fully comfortable” with this …
-
TV drug ad spending continues upward climb, logging nearly 30% growth in Q1
17 Apr 2025 18:29 GMT
… biggest-ticket ad for the full quarter.
Only one brand in … 35 million spent airing five ads across eczema, arthritis and ulcerative … , with $248 million spent advertising the top 10 drugs. That … is it? Novartis’ prostate cancer drug
Est. national TV ad spend: $ …
-
Novartis scores NFL deal to tackle health outcomes
17 Apr 2025 15:13 GMT
… starting with a 2003 sponsorship agreement that co-promoted … billion on TV ads, according to Ad Week.
Kennedy has … marketing plans.
The NFL already has several ongoing campaigns … relying solely on traditional advertising channels.”
Novartis will also have …
-
The Escalator: Real Chemistry, Noom, Novartis and more
17 Apr 2025 12:04 GMT
… U.S. corporate marketing at Novartis.
Board appointments:
The Ad Council named 17 … and elevated Carla Hassan, chief marketing officer at JPMorgan Chase, to …
-
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
31 Mar 2025 11:00 GMT
… including throughout areas impacted by AD such as the hippocampus, entorhinal … may escalate to decreased independence, communication challenges, behavioral disorders such as … Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences …
-
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
26 Mar 2025 17:35 GMT
EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings from Spherix’s fifth annual Patient Chart Dynamix™ : IgA …
-
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26 Mar 2025 08:30 GMT
REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC …
-
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™
05 May 2025 12:30 GMT
Delray Beach, FL, May 05, 2025 (GLOBE NEWSWIRE) -- The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching US$8.85 billion in 2024 and an impressive US$36.55 billion by 2032. Market …
-
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
05 May 2025 10:45 GMT
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies
Presented multiple clinical …
About
© 1995-2025